Atreca, Inc. (BCEL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...

The average one-year price target for Atreca Inc - (NASDAQ:BCEL) has been revised to 10.20 / share. This is an increase of 11.89% from the prior estimate of 9.12 dated July 5, 2023. The price target ...

BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, ...

BCEL has improved enrollment rates in its phase 1b ATRC-101 study, with 81 patients enrolled as of May 10, 2023. The company has enough cash to reach the readout from another round of data in the ATRC ...

Atreca, Inc.’s BCEL shares plunged about 37% on Aug 11, 2023, after the company reported structural changes in its business in the second-quarter earnings release, which failed to meet investors’ ...

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.’s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a ...